Abstract: A papaver from rhoeas' cell and tissue stain is formulated incorporating a new one bioflavonoid which specifically stains the nucleus for microscopic evaluation in histopathology, microbiology and cytology. It appears to be an alternative to hematoxylin for routine usage. Biochemical name of this compound is hydroxy-7-methoxy-2-(4-methoxy-3-(((2R,3R,4S,5S,6R)-3.4.5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3.4.5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2- yl)oxy)phenyl)-4H-chromen-4-one. NMR analysis shows the biochemical structure of molecule is a bioflavonoid. (FIG. 4,5) Molecule within Papaver rhoeas along with the synergistic and other molecules penetrates the biologic and nonbiologic samples. Combining with the other synergistic mechanisms the stain formula is prepared. The amount and type of Mordant and pH are the parameters that affect the quality and timing of the staining results.

Abstract: The present invention provides a biocompatible hydrogel composition comprising glycolipids and silk fibroin (SF) wherein glycolipid is preferably sophorolipids (SL). The said composition is useful in preparation of 3D scaffold for use in tissue engineering, and in the biomedical field. The present invention also provides a process for preparing such a composition and a process for acceleration of gelation time of silk fibroin (SF) in the presence of sophorolipid.

Abstract: A method for enhancing neurological health and development in a subject involving administering to the subject a nutritional composition including no greater than about 7 g/100 kcal of a fat or lipid source; no greater than about 7 g/100 kcal of a protein or protein equivalent source; at least about 5 g/100 kcal of a carbohydrate; and at least about 9 mg/100 kcal of inositol, wherein the ratio of exogenous inositol to inherent inositol is at least 50:50.

Abstract: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

Abstract: Microbial keratitis is a sight threatening disorder and infections result in ocular pain, stromal destruction, corneal thinning and/or perforation, leading to vision loss, if untreated and the need for transplantation. Methods of treating bacterial infection of the cornea prophylactically or therapeutically in a subject, are provided according to aspects of the present invention which include administering an effective dose of glycyrrhizin, or a pharmaceutically acceptable salt, hydrate, solvate, ester, amide, isomer or derivative thereof characterized by anti-bacterial activity, to the subject.

Abstract: The present invention relates to a heat-sterilized aqueous composition comprising a solubilized chitosan and glycerol. It also relates to a process of preparation of the same, as well as the use thereof, including compositions useful for the prevention and treatment of dry eye syndrome and arthritic diseases or disorders.

Abstract: Polycystic kidney disease is a cystic genetic disorder of the kidneys. Recent identification of signaling cascades de-regulated in PKD has led to the initiation of several clinical trials, but an effective therapy is still lacking. A new therapeutic paradigm is capable of improving the proliferation rate and cystic kidney volume in PKD.

Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornaviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5?-terminal end 40 bases of the positive-sense RNA strand of the virus.

Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.

Abstract: Disclosed is a synergistic beverage composition for alleviating alcohol-induced oxidative stress, hepatic stress, CNS stress, veisalgia and modulating immunology parameters. The composition includes saponin glycoside, amino acid derivative and sugar or sugar alcohol as active ingredients and pH adjusting agents and flavoring agents as inactive ingredients. The calculated proportions of amino acid derivatives, Saponin glycoside and sugar or sugar alcohol in the alcohol exhibit synergistic effects, thereby alleviating oxidative stress, hepatic stress, CNS stress, veisalgia and modulating immunology parameters, which could ultimately leads to prevention of alcohol-induced damage or impairment of organs, which could be temporary or permanent.

Abstract: There is provided a polymer-flavonoid conjugate, or a pharmaceutically acceptable salt thereof, uses thereof, and methods of making thereof. The disclosed polymer-flavonoid conjugates may be useful in the therapeutic and/or prophylactic treatment of a joint condition in a subject.

Abstract: The present invention relates to a chemical synthesis method for phillyrin. The method of the present invention comprises: first dissolving a glycosyl receptor phillygenin and a glycosyl donor in an organic solvent for glycosylation to obtain tetraacyl phillyrin; then dissolving the tetraacyl phillyrin in a second organic solvent, and adding sodium methoxide for deacylation, adding an acidic pH regulator to regulate the pH value of the reaction mixture to neutral; and finally carrying out purification treatment to obtain phillyrin. The advantages and practical values of the chemical synthesis method for phillyrin of the present invention lie in: the raw material is easy to get, the catalysts used for glycosylation are cheap and easy to get, the production cost is greatly reduced, and it can be used for industrial production.

Abstract: The present invention is concerned with a sterile aqueous ophthalmic solution comprising about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer. The invention is also concerned with a container containing said ophthalmic solution as well as the use thereof in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms.

Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

Abstract: A nucleic acid extraction method includes the following steps. Firstly, a mixture of a sample and a lysis buffer is provided. The pH of the lysis buffer is lower than 7. Then, the mixture of the sample and the lysis buffer is transferred to a nucleic acid catching chamber containing chitosan coating material, so that nucleic acid of the sample is bound to the chitosan coating material. Then, the chitosan coating material is washed with at least one wash buffer, thereby removing residual protein and cell debris. Then, the chitosan coating material is eluted with an elution buffer while heating the chitosan coating material, so that the nucleic acid is separated from the chitosan coating material. The pH of the elution buffer is higher than 7.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus pathologies.

Abstract: The present invention relates to isomerization of C4-C6 aldoses to their corresponding C4-C6 ketoses. In particular, the invention concerns isomerization of C4-C6 aldoses over solid zeolite catalysts free of any metals other than aluminum, in the presence of suitable solvent(s) at suitable elevated temperatures. C6 and C5 aldose sugars such as glucose and xylose, which are available in large amounts from biomass precursors, are isomerized to fructose and xylulose respectively, in a one or two-step process over inexpensive commercially available zeolite catalysts, containing aluminum as the only metal in the catalyst. The ketoses obtained are used as sweeteners in the food and/or brewery industry, or treated to obtain downstream platform chemicals such as lactic acid, HMF, levulinic acid, furfural, MMHB, and the like.

Abstract: The present invention discloses an application of ginsenoside Rg3 in preparing a medicine or product for preventing and treating dementia, and a preparation method thereof, which belong to the fields of medicines and health care products, and its products comprise a topical preparation, oral preparation and injection of the ginsenoside Rg3; and the Rg3 medicine or formulating prepared Rg3 compound medicine is prepared by using a solubilizer, a transdermal agent, a reagent promoting the absorption by penetrating a blood-brain barrier and an extractive, achieving the effect that the medicine penetrates the blood-brain barrier, and is used for preventing and treating dementia.